Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma

Human Pathology

Volumn 41, Issue 3, 2010, Pages 343-351

  Matsuura, Suguru ^a   Oda, Yoshinao ^a   Matono, Hiroshi ^a   Izumi, Teiyu ^a   Yamamoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Iwamoto, Yukihide ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

ADAM28; Cartilaginous bone tumors; Conventional chondrosarcoma; MMP13; MMP9

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 28 PROTEIN; ADAM PROTEIN; COLLAGENASE 3; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE TUMOR; CARTILAGE; CHONDROSARCOMA; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; ENCHONDROMA; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING;

ADAM PROTEINS; ADULT; BONE AND BONES; BONE NEOPLASMS; CHONDROMA; CHONDROSARCOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 75949092734     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.08.002     Document Type: Article

References (33)

1. Jodel S., Blavier L., Yoon J.M., et al. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 25 (2006) 35-43
2. Mochizuki S., and Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 98 (2007) 621-628
3. Seals D.F., and Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17 (2003) 7-30
4. Tousseyen T., Jonissen E., Reiss K., et al. (Make) stick and cut loose-disintegrin metalloproteases in development and disease. Birth Defects Res C Embryo Today 78 (2006) 24-46
5. Frolich C., Albrechtsen R., Dyrskjot L., et al. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 12 (2006) 7359-7368
6. Rocks N., Paulissen G., Quesasa C.F., et al. Expression of A disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer 94 (2006) 724-730
7. Carl-McGrath S., Lendeckel U., Ebert M., et al. The disintegrin-metalloproteases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 26 (2005) 17-24
8. Chang C., and Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 11 (2001) S37-43
9. Sakamoto A., Oda Y., Iwamoto Y., et al. Expression of membrane type 1 matrix metalloprotease, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. J Cancer Res Clin Oncol 125 (1999) 541-548
10. Hackel C.G., Krueger S., Grote H.J., et al. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer 89 (2000) 995-1003
11. Zyada M.M., and Shamaa A.A. Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness. Diagn Pathol 13 (2008) 3-26
12. Bjornsson J., McLeod R.A., and Unni K.K. Primary chondrosarcoma of long bones and limb girdles. Cancer 83 (1998) 2105-2119
13. Shintani Y., Higashiyama S., Ohta M., et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 64 (2004) 4190-4196
14. Zhao Z., Wen L.Y., Jin M., et al. ADAM28 participates in the regulation of tooth development. Arch Oral Biol 51 (2006) 996-1005
15. Kalinski T., Krueger S., Sel S., et al. ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma. Hum Pathol 38 (2007) 86-94
16. Romeo S., Bovée J.V., Jadnanansing N.A., et al. Expression of cartilage growth plate signalling molecules in chondroblastoma. J Pathol 202 (2004) 113-120
17. Buxbaum J.D., Liu K.N., Luo Y., et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273 (1998) 27765-27767
18. Schwettmann L., Wehmeier M., Jokovic D., et al. Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J Hepatol 49 (2008) 243-250
19. Okada A., Mochizuki S., Yatabe T., et al. ADAM-12 (meltrin alpha) is involved in chondrocyte proliferation via cleavage of insulin-like growth factor binding protein 5 in osteoarthritic cartilage. Arthritis Rheum 58 (2008) 778-789
20. Mckie N., Edwards T., Dallas D.J., et al. Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochem Biophys Res Commun 230 (1997) 335-339
21. Flannery C.R., Little C.B., Caterson B., et al. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol 18 (1999) 225-237
22. Kveiborg M., Albrechtsen R., Rudkjaer L., et al. ADAM12-S stimulates bone growth in transgenic mice by modulating chondrocyte proliferation and maturation. J Bone Miner Res 21 (2006) 1288-1296
23. Mitsui Y., Mochizuki S., Kodama T., et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res 66 (2006) 9913-9920
24. McGowan P.M., and Duffy M.J. Matrix metalloprotease expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 19 (2008) 1566-1572
25. Heist R.S., Marshall A.L., Liu G., et al. Matrix mealloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res 12 (2006) 5448-5453
26. Jones L.E., Humphreys M.J., Campbell F., et al. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10 (2004) 2832-2845
27. Kawashima A., Okada Y., Nakanishi I., et al. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol 142 (1997) 129-137
28. Uria J.A., Balbin M., Lopez J.M., et al. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am J Pathol 153 (1998) 91-101
29. Müller S., Söder S., Oliveira A.M., et al. Type II collagen as specific marker for mesenchymal chondrosarcomas compared to other small cell sarcomas of the skeleton. Mod Pathol 18 (2005) 1088-1094
30. Ayala G., Liu C., Nicosia R., et al. Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol 31 (2000) 341-346
31. Bovée J.V., Cleton-Jansen A.M., Rosenberg C., et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 189 (1999) 454-462
32. Staals E.L., Bacchini P., and Bertoni F. Dedifferentiated central chondrosarcoma. Cancer 106 (2006) 2682-2691
33. Huang L., Cheng Y.Y., Chow L.T., et al. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol 56 (2003) 116-120